Caprie study pdf download

The recent caprie trial clopidogrel versus aspirin in patients at risk of ischaemic. Highrisk groups in the caprie and cure studies would be expected to derive enhanced benefit from treatment with clopidogrel over that. During the caprie trial a change in secondary prevention strategies for vascular disease took place because of. Comparative benefits of clopidogrel and aspirin in highrisk. Clopidogrel versus aspirin in patients at risk of ischaemic events. At the end of your monthly term, you will be automatically renewed at the promotional monthly subscription rate until the end of the promo period, unless you elect to.

Offer starts on jan 8, 2020 and expires on sept 30, 2020. Lincoln hwy oak forest, il 60452 new lenox, il 60451 7086873020 8154853020. Is clopidogrel superior to aspirin in secondary prevention of vascular. Generalizing the results of clinical trials to actual practice. Comparative benefits of clopidogrel and aspirin in high. Caprie was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel 75 mg once daily and aspirin 325 mg once daily in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of. Participants were randomized to receive daily oral clopidogrel 75 mg or aspirin 325 mg. The cornerstone is clinical evidence from the caprie trial, a randomised, blinded, international study 1. The recent caprie trial clopidogrel versus aspirin in patients at risk of ischaemic events compared clopidogrel with aspirin in reducing the risk of vascular events in 19,185 patients with clinical manifestations of atherosclerosis.

A randomised, blinded, trial of clopidogrel versus aspirin. Article information, pdf download for results of the caprie trial. Methods caprie was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel 75 mg once daily and aspirin 325 mg once daily in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death. A randomised, blinded, trial of clopidogrel versus aspirin in patients. The caprie trial clopidogrel versus aspirin in patients at risk of. In the caprie study1 the event rate was at the lower level of that expected from other clinical trials, and recently published secondary prevention trials with lipid lowering agents showed similar low event rates in comparable risk groups. Details of the caprie study design and main findings have been reported elsewhere. The caprie study1 nov 16, p 29 shows that clopidogrel reduced by 87% the risk of cardiovascular events in the whole population, but this effect was not equally distributed in the three subgroups ischaemic stroke, recent myocardial infarction mi, and peripheral arterial disease. Results of the caprie trial 259 figure 1 cumulative risk of experiencing an event in the primary outcome cluster ischemic stroke, myocardial infarction, or vascular death. The recent caprie trial clopidogrel versus aspirin in patients at risk of. This study aimed to determine the efficacy and safety of moxifloxacin versus that of levofloxacin for the treatment of. The caprie study was conducted to evaluate the relative efficacy and safety of clopidogrel compared with asa in reducing the risk of occurrence of the composite primary outcome cluster of ischemic stroke is, mi, or vascular death vd, in patients at risk of ischemic events. Pdf communityacquired pneumonia recovery in the elderly.